Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka Shoots for Pharma Sales of 1.08 Trillion Yen in 2023
May 31, 2019
- Tokyo Court Dismisses Genentech’s Bid to Block Rituxan Biosimilar
May 30, 2019
- Japan Drug Firms’ Average Overseas Sales Ratio Nearly 50%, Offshore Biz Remains Way to Go as Home Market Falters: Tally
May 30, 2019
- Japan’s 1st ADA Deficiency Treatment Revcovi Now Available: Teijin Pharma
May 30, 2019
- Janssen Launches Simponi Autoinjector in Japan, Mitsubishi Tanabe in Charge of Distribution
May 30, 2019
- MSD/Bayer’s Rosuzet Now Available in Japan
May 29, 2019
- Takeda to Launch New Manufacturing Facility for Leuplin; Aims to Maintain Its 110 Billion Yen Sales
May 29, 2019
- Insulin/GLP-1 Receptor Agonist Combo Demonstrates Efficacy in Japan PIII: Sanofi
May 29, 2019
- NEC Ties Up with French Biotech to Develop Neoantigen Vaccines Using AI
May 28, 2019
- Ribomic Files Patent for Aptamer Therapeutic, Ends Licensing Pact with Otsuka
May 27, 2019
- Hisamitsu’s Hyperhidrosis Drug Hit Main Goal in Japan PII
May 27, 2019
- Hisamitsu One Step Closer to FY2019 Filing after NSAID Patch Delivers Positive PIII in Cancer Pain
May 27, 2019
- AbbVie’s Psoriasis Drug Skyrizi Makes Debut in Japan
May 27, 2019
- MSD’s Zerbaxa Launch Being Shelved after Foreign Particles Detected
May 27, 2019
- Big 3 Generic Makers Eke Out Growth in Japan, but Struggle in US; AG Momentum Continues: Jiho Tally
May 24, 2019
- Daiichi Sankyo Denies Report on Sales Deal on Its OTC Subsidiary
May 24, 2019
- Shionogi in Marketing Tie-Up with Molteni for Rizmoic
May 23, 2019
- Ono Offers Its Account of License Fee Row with Nobel Laureate
May 23, 2019
- Trelegy Hits Japan Shelves, Novartis Starts Accepting Orders for Kymriah
May 23, 2019
- AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…